AstraZeneca Shares Its Recipe For Partnering Success In Asia
This article was originally published in PharmAsia News
Just six months ago, century-old banks were closing their doors, job opportunities were dwindling, and the global economy faced a very uncertain future, but in Asia - particularly China - that situation is quickly turning around and companies need to prepare appropriately if they want tap into the region's potential, says AstraZeneca's Asia Pacific R&D VP Patrick Keohane
You may also be interested in...
AstraZeneca Invests $100 Million To Expand Shanghai Site In Move To Capture Larger Share Of Emerging Markets
SHANGHAI - AstraZeneca is investing $100 million to expand its current site in the Shanghai Zhangjiang Hi-Tech Park to strengthen its China headquarters and beef up marketing, R&D and academic training
TOKYO - AstraZeneca K.K., a fully owned Japanese subsidiary of AstraZeneca, has announced plans to market type 2 diabetes treatment dapagliflozin jointly with Bristol-Meyers Squibb in Japan, a company spokesman said
With two compounds already identified for screening - including one that fizzled in Phase II for melanoma - AstraZeneca kicked off a partnership with a pair of Singapore institutions to come up with drugs for liver cancer, a disease especially prevalent in East Asia, which accounts for 75 percent of the world's patients